FDA Suspends ORA Reforms and Field Laboratory Closures - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
FDA Suspends ORA Reforms and Field Laboratory Closures


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Rockville, MD (Aug. 3)—Commissioner Andrew von Eschenbach announced that the US Food and Drug Administration will not reform its Office of Regulatory Affairs until the Working Group on Import Safety finalizes its report evaluating import safety, according to the FDA News Drug Daily Bulletin.

Secretary Michael Leavitt of the US Department of Health and Human Services heads the working group, which was established on July 18, 2007 by executive order from the President. Von Eschenbach says the group will focus its attention on imported drugs, medical devices, and food. Within 60 days, the group is supposed to issue a set of recommendations to ensure the safety of imported products.

Leavitt has begun to hold meetings to prepare the report, and von Eschenbach attended some of the meetings. In addition, von Eschenbach has met with field agents to discuss what tools they need to inspect imported drugs and devices. He stated that FDA will need to hire more inspectors for certain locations. Von Eschenbach also aims to improve technology and standardize the agency’s system for inspections.

Reflecting von Eschenbach’s desire to re-evaluate FDA’s advisory committee process, the agency’s Office of Integrity and Accountability is examining when the agency decides to schedule advisory committee meetings, who serves on the committees, how FDA manages the committees, and how the committees can reflect diverse opinions.

In related news, von Eschenbach is also waiting for the working group report to be completed before he moves forward with plans to close more than half of FDA’s field laboratories.

 

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
When sourcing raw materials and non-GMP intermediates or other chemicals, where are the majority of your suppliers located?
In the United States
In Western Europe
In Central and Eastern Europe
In Japan
In India
In China
In the United States
20%
In Western Europe
18%
In Central and Eastern Europe
3%
In Japan
2%
In India
28%
In China
28%
View Results
Jim MillerOutsourcing OutlookJim Miller Time for a Model Upgrade
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Navigating the Global Pharmaceutical Supply Chain
Faiz kermaniSpotlightFaiz Kermani Reinvigorating European R&D innovation
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Biopharmaceutical Collaboration Is a Sign of the Times
Life After Big Pharma
PhRMA Details Its Proposal for Internet and Social-Media Standards
The Unregulated Regulator
Rx-360 Goals Get off the Ground
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here